New fund in the name of oncology research
Candriam has announced the launch of the Candriam Equities L Oncology Impact thematic equity fund to coincide with World Cancer Day 2019. Candriam already manages biotechnology, robotics and various ESG funds. Ten percent of the new fund's management fees will be donated by Candriam to leading European cancer research organizations.
The Candriam fund (LU1864481467) invests in listed companies developing products and services for the diagnosis and treatment of cancer. Science has made some progress in oncology, nevertheless the outlook for cancer patients is often still poor. Cancer is the second leading cause of death worldwide. Statistically, 40 percent of all men and women will receive a cancer diagnosis at some point in their lives. By 2030, the number of cancer deaths worldwide is expected to increase by 60 percent, from eight to 13 million annually (see Source 2).
Hope medical innovations
Immunotherapy, targeted therapy, liquid biopsy, tumor genome sequencing, nanotechnology, robotic surgery, artificial intelligence and Big Data - every day medical advances give new hope to cancer patients and their families. But innovations in cancer treatment also impact many other sectors, including biotechnology, pharmaceuticals, artificial intelligence and research, as well as companies around the world.
Candriam Equities L Oncology Impact supports the development of numerous new approaches to the diagnosis and treatment of cancer. The aim is to invest in breakthrough innovations that significantly improve the treatment of the disease.
Rudi Van den Eynde, Head of Thematic Equity at Candriam says: "There are many advances in the treatment of many diseases, especially cancer. We want to invest in companies with strong growth potential. With our expertise and twenty years of experience in managing a biotechnology fund, we are very well positioned to do so. The team includes two analysts with PhDs.It is also supported by an independent advisory group of leading cancer researchers."
High societal benefit expected
Vincent Hamelink, Chief Investment Officer of Investment Management adds: "New treatments and innovative technologies will continue to grow the international oncology market. Our new Candriam Equities L Oncology Impact is designed to generate returns for investors while also supporting cancer research - creating important societal benefits. By becoming even more involved in this area and also donating ten percent of the fund's management fee, we want to participate directly in the fight against cancer."
Candriam Equities L Oncology Impact is a sub-fund of Candriam Equities L, a Luxembourg SICAV (Société d'investissement à capital variable) managed by Candriam Luxembourg. The fund is currently authorized for distribution in the following countries: Austria, France, Germany, Italy, Luxembourg, the Netherlands, Portugal, Spain, Switzerland and the United Kingdom. Candriam, the innovative European asset manager already manages assets totaling over three billion euros in its biotechnology, robotics and demographics strategies.
2 Sources: National Institute of Health (NIH) and World Health Organization (WHO)
General note: To fully understand the risk profile of the fund, Candriam recommends that investors carefully read the official prospectus and risk description. The prospectus, the latest annual and semi-annual reports and other important information about the fund are available in English or in the language of the countries in which the fund is authorized for distribution.
